Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intensive Glycemic Control for Congestive Heart Failure Exacerbation

This study has been completed.
Information provided by (Responsible Party):
Kathleen Dungan, The Ohio State University Identifier:
First received: December 19, 2008
Last updated: July 14, 2014
Last verified: July 2014

Patients with heart failure often have high blood sugar (glucose).

Condition Intervention Phase
Congestive Heart Failure
Diabetes Mellitus
Drug: Intravenous insulin
Drug: Subcutaneous insulin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Intensive Glycemic Control for Congestive Heart Failure Exacerbation

Resource links provided by NLM:

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • Hospital Length of Stay [ Time Frame: Days ] [ Designated as safety issue: No ]
    Duration of hospitalization in days

Secondary Outcome Measures:
  • Hospital Readmission [ Time Frame: 30 days ] [ Designated as safety issue: No ]
    All-cause hospital readmission at 30 days after discharge

  • Heart Rate Variability [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
  • Quality of Life [ Time Frame: 30 day ] [ Designated as safety issue: No ]
  • Brain Natriuretic Peptide (BNP) [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
    Brain natriuretic peptide (BNP) was measured at day 3

  • Cardiac Index [ Time Frame: 72 hours ] [ Designated as safety issue: No ]

Enrollment: 74
Study Start Date: January 2009
Study Completion Date: May 2014
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intravenous Insulin Drug: Intravenous insulin
Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
Active Comparator: Subcutaneous Insulin
Basal bolus insulin (4 injections per day)
Drug: Subcutaneous insulin
Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.

Detailed Description:

Patients with heart failure often have high blood sugar. High glucose contributes to severe hospital complications and even death. Studies suggest that heart failure patients who have high glucose or diabetes do not live as long as patients with normal glucose. In this study, we will determine whether normalizing blood sugars using intravenous insulin short-term will improve outcomes in patients hospitalized for congestive heart failure. We enrolled patients with severe heart failure and randomly assigned them into 2 groups. We used intravenous (given through the vein) insulin to lower blood sugar levels in group 1, and insulin injections in group 2. We determined whether intravenous insulin improved hospital length of stay, rates of readmission, inflammatory markers, and cardiovascular tests that predict mortality in patients with heart failure.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 and above
  • Admitted (less than 48 hours) to the OSU Ross Heart Hospital with worsening heart failure
  • Hyperglycemia or diabetes. Hyperglycemia is defined as blood glucose greater than 150 mg/dL on at least 2 occasions separated by at least 4 hours apart, insulin use, or HbA1c >6.5%.

Exclusion Criteria:

  • Type 1 diabetes
  • Receiving comfort care measures only
  • Hospital stay expected to be less than 2 days
  • Pregnancy
  • Prisoners
  • Participation in the study on prior hospitalizations
  • Acute myocardial infarction within 3 months
  • End stage renal or liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00812253

United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Kathleen Dungan
Principal Investigator: Kathleen M Dungan, MD Ohio State University
  More Information

No publications provided

Responsible Party: Kathleen Dungan, Assistant Professor, The Ohio State University Identifier: NCT00812253     History of Changes
Other Study ID Numbers: 2007H0197, 1K23DK080891-01A1
Study First Received: December 19, 2008
Results First Received: June 12, 2014
Last Updated: July 14, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Ohio State University:
Heart failure
Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Failure
Cardiovascular Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Heart Diseases
Metabolic Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 20, 2014